Clinical Trial Update: Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and pharmacokinetic study of RVX000222 in healthy subjects and individuals with low HDL cholesterol completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Disease
• Coronary Syndrome
• Dyslipidemia

Drugs mentioned

• RVX000222 (apabetalone)

Snippet

Sponsor: Resverlogix Corp | Conditions: Dyslipidemia, Atherosclerosis | Phase 1, Phase 2 | Status: COMPLETED